Granahan Investment Management LLC Has $7.39 Million Holdings in Soleno Therapeutics, Inc. $SLNO

Granahan Investment Management LLC grew its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 82.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,253 shares of the company’s stock after acquiring an additional 49,276 shares during the period. Granahan Investment Management LLC owned 0.20% of Soleno Therapeutics worth $7,386,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. CenterBook Partners LP increased its holdings in shares of Soleno Therapeutics by 156.2% in the third quarter. CenterBook Partners LP now owns 62,794 shares of the company’s stock valued at $4,245,000 after purchasing an additional 38,282 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Soleno Therapeutics by 255.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 280,984 shares of the company’s stock worth $18,995,000 after buying an additional 201,983 shares in the last quarter. Castleark Management LLC bought a new position in Soleno Therapeutics in the 2nd quarter valued at $2,919,000. TimesSquare Capital Management LLC boosted its position in Soleno Therapeutics by 52.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 377,566 shares of the company’s stock valued at $25,523,000 after buying an additional 130,197 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Soleno Therapeutics by 133.0% in the 2nd quarter. Marshall Wace LLP now owns 288,334 shares of the company’s stock valued at $24,157,000 after buying an additional 164,580 shares during the period. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SLNO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wells Fargo & Company decreased their price target on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. TD Cowen lowered their price objective on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.85.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Recent operational data: Soleno reported quarterly results on Feb. 25 that beat consensus — $0.80 EPS vs. $0.64 estimate and revenue roughly $91.7M vs. ~$88.6M — a near‑term fundamental positive that may temper downside if litigation risk abates.
• Negative Sentiment: Class action filings allege Soleno misled investors about the integrity, safety and results of its DCCR Phase 3 program, citing the company’s Nov. 5, 2025 disclosures; the Hagens Berman notice is a representative filing. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple national plaintiff firms (Robbins Geller, Schall, Kessler Topaz, Rosen, Glancy Prongay, Levi & Korsinsky, etc.) are actively soliciting clients and reminding investors of the May 5, 2026 lead‑plaintiff deadline, increasing the likelihood of consolidated litigation and potential settlement exposure. Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
• Negative Sentiment: Allegations across notices include claims of concealed safety issues, material misstatements/omissions about trial conduct and efficacy, and even charges of “sham” trials — outcomes that, if substantiated, could lead to regulatory inquiry, management distraction, legal costs and damages payments.

Soleno Therapeutics Stock Performance

SLNO stock opened at $33.76 on Monday. The business’s fifty day moving average is $40.74 and its 200-day moving average is $50.93. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.74 billion, a P/E ratio of 146.79 and a beta of -3.16. Soleno Therapeutics, Inc. has a twelve month low of $32.63 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Equities research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.